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Introduction: Pulmonary vein reconnection after pulmonary vein isolation (PVI) is a signif-
icant problem in the treatment of paroxysmal atrial fibrillation (AF). We report about pa-
tients who underwent contact force (CF) guided PVI using CF catheter and compared them
to patients with PVI using an ablation catheter with enhanced tip irrigation.
Methods: A total of 59patientswere included in the analysis. In 30 patients circumferential PVI
was performed using the Thermocool Smarttouch® ablation catheter (ST) whereas in 29 pa-
tients circumferential PVI using theThermocool SurroundFlowSF® ablation catheter (SF)was
performed. Patients were compared in regard to procedure time, fluoroscopy time/dose as
well asRF-applicationdurationandcompletenessofPVI.Adverseevents (pericardial effusion,
PV stenosis, stroke, death) were evaluated. The presence of sinus rhythm off antiarrhythmic
medication was assessed during 6 months follow-up using multiple 7 day Holter-ECGs.
Results: In both groups, all PVs were isolated without serious adverse events. Procedure
time was 2.15 ± 0.5 h (ST) vs. 2.37 ± 1.13 h (SF) (p ¼ 0.19). Duration of RF-applications was
46.6 ± 18 min (ST) and 49.8 ± 19 min (SF) (p ¼ 0.52). Fluoroscopy time was 25.2 ± 13 min (ST)
vs. 29 ± 18 min (SF), fluoroscopy dose 2675.6 ± 1658 versus 3038.3 ± 1997 cGym2 (p ¼ 0.36
and 0.46 respectively). Sinus rhythm off antiarrhythmic medication validated with 7 day
Holter ECGs was present in both groups in 72% of patients after 6 months of follow up.
Conclusion: PVI using the new contact force catheter is safe and effective in patients with
paroxysmal AF.
Copyright © 2015, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).rsit€at Mu¨nchen, Medizinische Klinik I, Marchioninistr. 15, 81377 Mu¨nchen, Germany. Tel.:
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accepted treatment option in patients with paroxysmal atrial
fibrillation [1e3]. Although treatment expertise and technical
equipment improve, about 30% of patients need a repeat
ablation procedure due to arrhythmia recurrence. It has been
seen that PV reconnection is the commonest cause of AF
recurrence in patients undergoing a repeat ablation procedure
[4e7].
Recent preclinical research showed that the contact force
between the catheter tip and the target tissue is a key factor to
safe and effective lesion formation [8,9]. Insufficient contact
may result in an ineffective lesion, leading to arrhythmia
recurrence, whereas excessive contact force may result in
complications such as perforation [9].
In a first safety and efficacy study [10] using the TactiCath
ablation catheter (Endosense SA, Geneva, Switzerland)
feasibility and safety of a contact force system was
demonstrated.
We report one of the first series of patientswho underwent
contact force aided PVI using the Smarttouch® contact force
ablation catheter used in conjunction with the Smarttouch
software for the Carto3 mapping system (Biosense-Webster,
Diamond Bar, CA, USA) and compared them to patients who
underwent PVI using the Surround Flow (SF)® ablation cath-
eter with the Carto3 system (Biosense-Webster, Diamond Bar,
CA, USA) which was developed to provide better lesion for-
mation by an enhanced irrigation of the catheter tip surface
[11].Methods
Patients
Between 05/2011 and 03/2012, a total of 59 patients with drug
refractory paroxysmal AF and normal left ventricular function
were consecutively included in the study. Contact force
guided pulmonary vein isolation (PVI) was performed in 30
patients whereas PVI using the SF enhanced irrigation abla-
tion catheter was performed in 29 patients. Patients with
persistent AF, atrial tachycardia or additional other arrhyth-
mias than paroxysmal AF were excluded from the study.
Procedure
Patients were kept on continuous oral anticoagulation with
intra-procedural INR levels of 2.0e2.7 or continued taking
Dabigatran. Ablation procedures were performed under
conscious sedation using a three-dimensional mapping sys-
tem for anatomy and catheter visualization (Carto3,
Biosense-Webster, Diamond Bar, CA, USA). The individual
left atrial anatomy as segmented from the previous CT scan
was displayed during the procedure and fused with the
reconstructed anatomy in the 3D mapping system if felt
appropriate (see Fig. 1). An 8-polar catheter was placed in the
coronary sinus (CS; XPT, C.R. Bard, Lowell, MA; USA) and the
left atrium (LA) was accessed by single or double transseptalpuncture or via an open foramen ovale. Preablation and
postablation angiograms of all PVs were performed. After
placement of electrode catheters within the left atrium,
heparin was given to maintain an activated clotting time at
270 s.
PVI was performed using a circular steerable mapping
catheter (Lasso™, Biosense-Webster, Diamond Bar, CA,
USA) and an irrigated tip ablation catheter. In the contact
force group the Biosense Thermocool Smarttouch® ablation
catheter was used with a flow rate of 30 ml/min, a
maximum temperature of 43 C and a maximum power of
25e30 W (ST group). Smarttouch uses a force sensing sys-
tem based on pressure applied to the tip, which integrates a
nitinol spring and pressure sensor. The system was devel-
oped to integrate with the Biosense Carto3 mapping system.
A contact force of 10e20 g as recommended by the company
was aimed for. There was an online contact force reading
available during mapping, as well as during RF application.
In addition, color coded contact force was displayed on the
anatomical map (see Fig. 1). In the conventional group all
patients underwent PVI with the Biosense Thermocool
Surround Flow SF® ablation catheter (SF group) with a flow
rate of 17 ml/min and a maximum power of 25e30 W until
electric PV isolation confirmed with the circular mapping
catheter was achieved. The ThermoCool Surround Flow
catheter was developed with improved irrigation provided
by 56 very small holes (0.003500) positioned around the entire
electrode, holding the potential to decrease the required
irrigation flow rate and allow to deliver high RF power even
in areas of very low blood flow [11]. In all patients circum-
ferential PVI circulating both ipsilateral PVs was performed
(see Fig. 1). Entry and exit block (pacing anterior, inferior,
superior, posterior of the PVI with 10 V and 2 ms) were
documented in all patients and all PVs. To avoid too much
diversity in the two groups same operators performed the
ablation procedures.Post procedural management
Patients were kept on oral anticoagulation after PVI. In all
patients beta blockers were recommended. No other antiar-
rhythmic medications were prescribed. If patients were on
antiarrhythmic drugs before the procedure, these were
discontinued.Follow-up after ablation
Patients were scheduled for visits in the arrhythmia clinic at 3
and 6 months after the ablation. At each visit, intensive
questioning for arrhythmia-related symptomswas done and a
7-day Holter-ECG was performed. Success was defined as no
documented symptomatic or asymptomatic AF or atrial
tachycardia (AT) episode > 30 s after a blanking period of 6
weeks off antiarrhythmicmedication. If no AF recurrence was
detected within the first 3 months and the CHADS2 score was
2, oral anticoagulation was discontinued. No antiarrhythmic
medications besides beta blockers were used after the abla-
tion procedure.
Table 1 e Baseline characteristics.
Data Surround Flow
catheter group
N ¼ 29
Smarttouch
catheter group
N ¼ 30
P value
Fig. 1 e Anterior (left side) and posterior view of an anatomical map of the left atriummerged with a cardiac CT image of the
same patients using the Carto3 System. Pulmonary veins were circumferentially isolated using a contact force
measurement system (Thermocool Smarttouch catheter, Biosense Webster). The color-coding shows good contact (green to
blue) or bad contact (red) on the map. The shown number 17 on the left and 18 on the right side shows the online contact
force in grams.
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Statistic Tests were performed using SPSS 20. All values are
presented as mean ± SD. Student's t-test, Fisher's exact test,
Wilcoxon's test and Chi-square test were applied for com-
parisons. A probability value of p < 0.05 was considered sta-
tistically significant. Test for normal distribution was done
using the KolmogoroveSmirnov Test.
Age 61 ± 12 59.1 ± 10 0.53
Gender male 48% 53% 0.7
Art. Hypertension 52% 55% 0.8
Coronary artery
disease
10% 17% 0.7
Diabetes mellitus 10% 7% 1.0
Previous stroke 7% 0 0.5
Body mass index 22.5 ± 3 23.6 ± 3 0.22
Duration of AF in
months
33.1 ± 33 55.2 ± 53 0.13
Episodes per year 157 ± 160 123.8 ± 138 0.59
Size of left atrium
mmode/
planimetric mm2
40.4 ± 4/22 ± 5 43.6 ± 8/22.0 ± 6 0.08/0.96
Anticoagulation
with warfarin
With new
anticoagulants
90%
0%
72%
24%
0.014
Previous beta
blocker
72% 71% 0.93
Previous class Ic or
III
antiarrhythmic
drug
77% 65% 0.33Results
Patients' characteristics
Baseline characteristics did not differ between the patients
included in ST group compared to patients included in the SF
group (see Table 1). Patients in the ST group were 59.1 ± 10
years old, 53% were male and suffered from paroxysmal AF
since 55.2 ± 53 months. Patients in the SF group were 61 ± 12
years old, 48% of them were male and suffered from parox-
ysmal AF since 33.1 ± 33 months.
Procedural data
PVs were successfully isolated in all patients in both groups.
Procedural durationwas comparable between both groups (ST
2.15 ± 0.5 h, SF 2.37 ± 1.13 h p ¼ 0.19 respectively). In addition
fluoroscopic time and dose showed a slight tendency to be
lower in the ST versus the SF group (25.2 ± 13 min vs.
i n d i a n p a c i n g and e l e c t r o p h y s i o l o g y j o u r n a l 1 5 ( 2 0 1 5 ) 1 5 2e1 5 7 15529 ± 18 min, p ¼ 0.36 and 2675.6 ± 1658 cGym2 vs.
3038.3 ± 1997 cGym2, p ¼ 0.46 respectively). Likewise, the RF
time required was slightly lower in the ST vs. the SF group
(46.6 ± 18 min vs. 49.8 ± 19 min, p ¼ 0.52) (See Table 2).
Adverse events
Overall, adverse events were low. No patient suffered from a
cardiac tamponade, stroke, significant PV stenosis >50% or
esophageal fistula. No catheter charring was observed. Minor
complications were seen in two patients from the SF group:
one with a small AV fistula and one with a pseudoaneurysm.
Both patients were managed without surgical intervention.
Freedom from atrial arrhythmia 6 months after PVI
Follow up after 6 months was available for 29/29 patients in
the SF and 29/30 patients in the ST group. In both groups, 72%
of patients showed stable sinus rhythm clinically and on 7-
day-Holter ECGs off antiarrhythmic medication.Discussion
Main findings
To our knowledge this is the first study comparing two new
strategies to improve lesion formation during RF ablation: The
new contact force measurement with the enhanced irrigation
of the ablation catheter tip. Moreover, it is the first report with
a midterm follow up after PVI using the contact force guided
system showing that the new system was very safe and
equally effective acutely and during a 6 months follow-up
compared to the enhanced irrigated tip ablation catheter
approach. A tendency towards a shorter procedure time,
lower fluoroscopic time and dose and a reduced RF time was
noted with the new system but did not reach statistical
significance.
Usefulness of contact force measurement
In the first study using the TactiCath ablation catheter
(Endosense SA, Geneva, Switzerland) feasibility and safety of a
contact force system was demonstrated [10]. In this study aTable 2 e Procedural data.
Data Surround Flow
catheter group
N ¼ 29
Smarttouch
catheter group
N ¼ 30
P
value
Procedure
time (hours)
2.37 ± 1.13 2.15 ± 0.5 0.19
Fluoroscopic
time
(minutes)
29 ± 18 25.2 ± 13 0.36
Fluoroscopic
dose
(cGym2)
3038.3 ± 1997 2675.6 ± 1658 0.46
RF time
(minutes)
49.8 ± 19 46.6 ± 18 0.52total of 43 patients underwent right sided SVT ablation and 34
patients underwent ablation for AF. Operators were blinded
during mapping phase regarding the contact force used.
Variability of contact force between operators and different
areas of the atriums differed highly. In one patient a cardiac
tamponade occurred; directly before this event a very high
contact force with 137 g was recorded.
In another small study [12] using the TactiCath catheter 22
patients underwent circumferential PVI. Operators were
blinded to the used contact force. In this study no adverse
events occurred. In this study again the contact force varied
widely showing best contact force on the left side at the su-
perior and inferior side and worst contact at the anterior side;
on the right side best contact was achieved anterior and
inferior and worst contact at the carina. Acute PV reconnec-
tion after adenosine application occurred only in areas with
previous low contact force (for the left sided PVs 8.3 ± 6.7 g vs.
18 ± 12.7 g, and for the right sided PVs 10.8 ± 6.8 g vs.
24.5 ± 14.8 g respectively).
In the data of the Efficas I trial [13] 40 patients underwent
PVI with the operator blinded to the applied contact force.
After 3 months the majority of patients underwent repeat
ablation procedure regardless of arrhythmia recurrence. In 26
patients 52 gaps out of 318 segments were recorded. In the
segments with the recorded gaps contact force was lower
compared to segments without recorded gaps. In the Efficas
trial likewise the TactiCath system was used. These first data
of the TactiCath catheter showed very promising results,
however larger studies proving the concept are still missing.
The TactiCath Force-Sensing Irrigated Ablation Catheter
(Endosense), which received regulatory approval in Europe in
May 2009, has three optical fibers that emit wavelengths.
When the catheter tip touches tissue, the optical fibers bend.
TactiCath's software calculates the changes in the wave-
lengths between the optical fibers and translates this infor-
mation into a measurement of how much pressure is being
applied to the heart tissue the Smarttouch catheter however
uses a force sensing system based on pressure applied to the
tip, which integrates a nitinol spring and pressure sensor. The
system was developed to integrate with the Biosense Carto3
mapping system. Up until nowno study exist which compares
the differences between the two systems therefore only the
force sensing itself can be compared.
Enhanced lesion formation: strategies and results
In both groups all PVs were successfully isolated and no
catheter related complications occurred. In patients treated
with the contact force guided catheter there was no statistical
significance difference regarding a reduced procedure time,
reduced fluoroscopic time or lower RF time required to
completely isolate all PVs. Up to now, only very limited data is
available regarding contact force guided PVI, especially con-
cerning the Smarttouch ablation catheter used in this study.
In one small study using the ST system [14] 40 patients
were assigned to circumferential PVI either with contact force
guidance available or with the operator blinded to the used
contact force. Complete PVI could be achieved in all patients.
The endpoint was acute reconnection after a waiting period of
1 h and use of adenosine. In the groupwith the known contact
i n d i a n p a c i n g and e l e c t r o p h y s i o l o g y j o u rn a l 1 5 ( 2 0 1 5 ) 1 5 2e1 5 7156force acute reconnection was significantly lower with 4% vs.
21%. In this study procedure time was comparable in both
groups and fluoroscopic time showed a slight tendency to be
lower in the group with the known contact force. As in our
study, adverse events were rare.
In another study [15] using the ST catheter in one group
and the standard Navistar Thermocool (Biosense Webstar)
catheter in the other group a significant reduction in RF time
and procedure time required was observed. However, in the
current study the Surround Flow catheter was used for com-
parison. In a study by Bertaglia et al. [11]. were the Thermocool
Navistar catheter was compared to the Thermocool Surround
Flow catheter showing a higher acute PVI success after a
waiting period of 30 min in the group with the SF catheter; the
fact that we compared two ablation catheters that are both
supposed to be more effective than conventional catheters
could explain thatein contrast to the study by Martinek et al.
[15] e we could not detect any significant difference between
both approaches.Freedom from atrial arrhythmias
After a follow up of 6 months 72% of patients in both groups
were free from atrial arrhythmias of >30 s off antiarrhythmic
medication. Up to now no study published follow up data
regarding the ST catheter. In a sub-study of the Toccata trial
using patients who underwent PVI a small number of patients
(5/5) treated with a contact force <10 g showed arrhythmia
recurrence, whereas patients treated with an average contact
force >20 g experienced stable sinus rhythms after a follow up
of 12 months [16]. These results were obtained from a very
small patient group using a different contact force system.
Nevertheless, the effective contact force still has to be
investigated.Limitations
This study was not a randomized study although patients
were consecutively included. Because of small patient
numbers and follow up of 6 months results could be mis-
interpreted. If PVI reconnection occurred at the end of the
procedure, these PVs were reisolated; however, no analysis of
occurring gaps and areas of low contact force was performed.Conclusion
PVI using the new contact force catheter is safe and effective
in patients with paroxysmal AF. Procedural characteristics as
procedure duration, RF time and fluoroscopy time were not
different using contact force measurement as compared to an
ablation approach using enhanced ablation catheter tip irri-
gation. Contact force guided PVI reached the same success
rate as PVI using enhanced tip irrigation after 6 months of
follow-up. It has to be shown in larger studies if there is a
definite advantage using the contact force catheter. A pro-
spective multicenter trial testing for efficacy and safety is on
its way and results are expected in 2014 [17].Conflict of interest
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